Company intelligence / Profile preview

Elad Biotech

Jinan, Shandong province, Chinasana.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The company has conducted multiple clinical trials with 627 patients across the US, UK, EU, China, and Singapore. A pivotal Phase 3 trial in severe alcoholic hepatitis completed in 2018 showed numerical improvement in survival between three months and one year, but failed to meet the primary endpoint of significant improvement in overall survival through at least 91 days[1][5].

Therapeutic areas: Gastroenterology
Modalities: Cell therapyExtracorporeal therapy
Industry: Biotech

Drug pipeline

1 asset

ELAD

Phase 3

Indications: Liver failure, Acute-on-chronic liver failure, Alcoholic hepatitis

Beyond the preview

Go deeper on Elad Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elad Biotech.

Explore the full profile